Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02176018 · ClinicalTrials.gov registry record · Phase 2
Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine
A Phase 2 study, sponsored by Cady, Roger, M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT02176018 is a Phase 2 study that has completed, run by Cady, Roger, M.D.. The registered enrollment target is 76 participants.
The verdict
NCT02176018, a Phase 2 study, has completed, sponsored by Cady, Roger, M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and effectiveness of daily dextromethorphan/quinidine (Nuedexta) in reducing the frequency and progression of episodic migraine.
Interventions
- DRUG Placebo
- DRUG Dextromethorphan and quinidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2014-08 |
| Est. Completion | 2017-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02176018
The ClinicalTrials.gov registry entry for NCT02176018 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cady, Roger, M.D., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02176018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02176018 about?
NCT02176018 is a clinical study titled "Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine". The purpose of this study is to evaluate the efficacy and effectiveness of daily dextromethorphan/quinidine (Nuedexta) in reducing the frequency and progression of episodic migraine.
What is the current status of trial NCT02176018?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2014-08. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02176018?
The interventions under investigation include: Placebo (DRUG), Dextromethorphan and quinidine (DRUG).
Who is sponsoring clinical trial NCT02176018?
This trial is sponsored by Cady, Roger, M.D., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.